Article thumbnail

Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy

By Daniel Z Lieberman and Suena H Massey
Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2899788
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A budget-impact and cost-effectiveness model for second-line treatment of major depression.
  2. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
  3. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther.
  4. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
  5. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.
  6. (2001). A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health.
  7. (2003). A national study of the effect of chronic pain on the use of health care by depressed persons. Psychiatr Serv.
  8. (2008). A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol.
  9. (2005). A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin.
  10. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
  11. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
  12. (2007). A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol.
  13. American Psychiatric Association. Practice guideline for major depressive disorder in adults.
  14. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry.
  15. (1996). Analgesic drugs for neuropathic and sympathetically maintained pain. Clin Geriatr Med.
  16. (2005). Antidepressants for neuropathic pain. Cochrane Database Syst Rev.
  17. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
  18. (2006). Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study. Curr Med Res Opin.
  19. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale.
  20. (1994). Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Ed.
  21. (1994). Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder. Ann Clin Psychiatry.
  22. (1996). Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl.
  23. (2008). Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry.
  24. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
  25. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK.
  26. Cost-effectiveness of venlafaxine for the treatment of major depression in hospitalized patients.
  27. Depressive symptom profiles and severity patterns in outpatients with psychotic vs nonpsychotic major depression.
  28. Differential physiological effects of a low dose and high doses of venlafaxine in major depression.
  29. (2005). Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother.
  30. Duloxetine in the treatment of depression: a double-blind placebocontrolled comparison with paroxetine.
  31. Efficacy of bupropion in tricyclic-resistant or intolerant patients.
  32. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder.
  33. (2008). Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol.
  34. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs venlafaxine extended-release formulation.
  35. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.
  36. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports.
  37. Initiation and adaptation: a paradigm for understanding psychotropic drug action.
  38. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry.
  39. NaRIs: new agents for the treatment of depression.
  40. (1981). National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. Arch Gen Psychiatry.
  41. National trends in the outpatient treatment of depression.
  42. Nefazodone-induced liver failure.
  43. (2002). Organization. The World Health Report 2002: Reducing Risks. Promoting Healthy Life. Geneva, Switzerland: World Health Organization;
  44. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.
  45. (2000). Pharmacoeconomic studies of antidepressants: focus on venlafaxine. Depress Anxiety.
  46. Placebo response in studies of major depression: variable, substantial, and growing.
  47. (2008). Pristiq [package insert],
  48. (2002). Projections of global mortality and burden of disease from
  49. (2006). Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry.
  50. (1991). Psychiatric Disorders in America: The Epidemiologic Catchment Area Study.
  51. (1994). Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ.
  52. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms.
  53. Reliability of DSM-IV anxiety and mood disorders: implications for the classification of emotional disorders.
  54. (2002). Residual symptoms in depression: An emerging therapeutic target. Prog Neuropsychopharmacol Biol Psychiatry.
  55. (2002). Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys’ estimates. Arch Gen Psychiatry.
  56. (2008). safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin.
  57. (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry.
  58. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.
  59. sertraline, or venlafaxine-XR after failure of SSRIs for depression.
  60. (1997). Suicide as an outcome for mental disorders. A meta-analysis.
  61. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants.
  62. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).
  63. (1998). The global burden of disease, 1990–2020. Nat Med.
  64. (1990). The Global Burden of Disease. A comprehensive assessment of mortality and disability from diseases. injuries and risk factors in
  65. The making of a user friendly MAOI diet.
  66. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression.
  67. The NIMH Depression Awareness, Recognition, and Treatment Program: structure, aims, and scientific basis.
  68. The pharmacoeconomics of venlafaxine in depression.
  69. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence.
  70. Timing of onset of antidepressant response with fluoxetine treatment.
  71. Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis.
  72. Tricyclic antidepressant overdose: incidence of symptoms.
  73. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.